Rosiglitazone Reduces Plasma Levels of Inflammatory and Hemostatic Biomarkers and Improves Global Endothelial Function in Habitual Heavy Smokers Without Diabetes Mellitus or Metabolic Syndrome

Journal of the Formosan Medical Association

Volumn 109, Issue 2, 2010, Pages 113-119

  Chen, I Chih ^a,c   Chao, Ting Hsing ^a,b,d   Tsai, Wei Chuan ^a,b   Li, Yi Heng ^a,b  

^a Division of Cardiology   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c TAINAN MUNICIPAL HOSPITAL   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

endothelium; metabolic syndrome; peroxisome proliferator activated receptor; rosiglitazone; smoking

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; FIBRINOGEN; GELATINASE B; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PADGEM PROTEIN; PLACEBO; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; GLUCOSE BLOOD LEVEL; HEMOSTASIS; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; MALE; NORMAL HUMAN; PHOTOELECTRIC PLETHYSMOGRAPHY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SENSITIZATION; SMOKING; TREATMENT DURATION; VASODILATATION;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; ENDOTHELIUM; ENDOTHELIUM-DEPENDENT RELAXING FACTORS; FIBRINOGEN; HEMOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PHOTOPLETHYSMOGRAPHY; SMOKING; THIAZOLIDINEDIONES;

EID: 77649106304     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/S0929-6646(10)60031-9     Document Type: Article

References (44)

1. Raskin P., Rappaport E.B., Cole S.T., et al. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 43 (2000) 278-284
2. Parulkar A.A., Pendergrass M.L., Granda-Ayala R., et al. Non-hypoglycemic effects of thiazolidinediones. Ann Intern Med 134 (2001) 61-71
3. Duan S.Z., Usher M.G., and Mortensen R.M. Peroxisome prolifer-ator-activated receptor-gamma-mediated effects in the vasculature. Circ Res 102 (2008) 283-294
4. Tseng C.H., and Huang T.S. Pioglitazone with sulfonylurea: glycemic and lipid effects in Taiwanese type 2 diabetic patients. Diabetes Res Clin Pract 70 (2005) 193-194
5. Haffner S.M., Greenberg A.S., Weston W.M., et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes melli-tus. Circulation 106 (2002) 679-684
6. Nordt T.K., Peter K., Bode C., et al. Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells. J Clin Endocrinol Metab 85 (2000) 1563-1568
7. Marx N., Froehlich J., Siam L., et al. Antidiabetic PPARγ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 23 (2003) 283-288
8. Randriamboavonjy V., Pistrosch F., Bölck B., et al. Platelet sarcoplasmic endoplasmic reticulum Ca2+-ATPase and mu-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone. Circulation 117 (2008) 52-60
9. Yu J., Jin N., Wang G., et al. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease. Metabolism 56 (2007) 1396-1401
10. Rosmarakis E.S., and Falagas M.E. Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials. Am Heart J 154 (2007) 144-150
11. Sorrentino S.A., Bahlmann F.H., Besler C., et al. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes melli-tus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 116 (2007) 163-173
12. Raji A., Seely E.W., Bekins S.A., et al. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 26 (2003) 172-178
13. Wang T.D., Chen W.J., Lin J.W., et al. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol 93 (2004) 362-365
14. Esposito K., Ciotola M., Carleo D., et al. Effect of rosiglita-zone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care 29 (2006) 1071-1076
15. Chinetti G., Fruchart J.C., and Staels B. Peroxisome proliferators-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 49 (2000) 497-505
16. Inoue I., Katayama S., Takahashi K., et al. Troglitazone has a scavenging effect on reactive oxygen species. Biochem Biophys Res Commun 235 (1997) 113-116
17. Chen Z., Ishibashi S., Perrey S., et al. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice. Pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 21 (2001) 372-377
18. Li A.C., Brown K.K., Silvestre M.J., et al. Peroxisome proliferators-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106 (2000) 523-531
19. Shiomi T., Tsutsui H., Hayashidani S., et al. Pioglitazone, a peroxisome proliferators-activated receptor-γ agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 106 (2002) 3126-3132
20. Willett W.C., Green A., Stampfer M.J., et al. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med 317 (1987) 1303-1309
21. Li Y.H., Chen J.H., Tsai W.C., et al. Synergic effect of thrombomodulin promoter-33G/A polymorphism and smoking on the onset of acute myocardial infarction. Thromb Haemost 87 (2002) 86-91
22. Teng J.K., Lin L.J., Tsai L.M., et al. Acute myocardial infarction in young and very old Chinese adults: clinical and therapeutic implications. Int J Cardiol 44 (1994) 29-36
23. Zeiher A.M., Schächinger V., and Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary artery vasodilator function. Circulation 92 (1995) 1094-1100
24. Tracy R.P., Psaty B.M., Macy E., et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol 17 (1997) 2167-2176
25. Blann A.D., Steele C., and McCollum C.N. The influence of smoking on soluble adhesion molecules and endothelial cell markers. Thromb Res 85 (1997) 433-438
26. Sharp D.S., Benowitz N.L., Bath P.M., et al. Cigarette smoking sensitizes and desensitizes impedance-measured ADP-induced platelet aggregation in whole blood. Thromb Haemost 74 (1995) 730-735
27. Nakamura T., Ebihara I., Shimada N., et al. Effect of cigarette smoking on plasma metalloproteinase-9 concentration. Clin Chim Acta 276 (1998) 173-177
28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NECP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
29. Chao T.H., Tsai L.M., Tsai W.C., et al. Effect of atrial fibrillation on pulmonary venous flow patterns assessed by Doppler transesophageal echocardiography. Chest 117 (2000) 1546-1550
30. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
31. Hijmering M.L., Stroes E.S., Pasterkamp G., et al. Variability of flow mediated dilation: consequences for clinical application. Atherosclerosis 157 (2001) 369-373
32. De Roos N.M., Bots M.L., Schouten E.G., et al. Within-subject variability of flow-mediated vasodilation of the brachial artery in healthy men and women: implications for experimental studies. Ultrasound Med Biol 29 (2003) 401-406
33. Malik J., Wichterle D., Haas T., et al. Repeatability of noninvasive surrogates of endothelial function. Am J Cardiol 94 (2004) 693-696
34. McEniery C.M., Wallace S., Mackenzie I.S., et al. Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans. Hypertension 48 (2006) 602-608
35. Chowienczyk P.J., Kelly R.P., MacCallum H., et al. Photoplethysmographic assessment of pulse wave reflection. J Am Coll Cardiol 34 (1999) 2007-2014
36. Hayward C.S., Kraidly M., Webb C.M., et al. Assessment of endothelial function using peripheral waveform analysis. A clinical application. J Am Coll Cardiol 40 (2002) 521-528
37. Wilkinson I.B., Hall I.R., MacCallum H., et al. Pulse wave analysis. Clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function. Arterioscler Thromb Vasc Biol 22 (2002) 147-152
38. Gopaul N.K., Manraj M.D., Hébé A., et al. Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism. Diabetologia 44 (2001) 706-712
39. Hetzel J., Balletshofer B., Rittig K., et al. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol 25 (2005) 1804-1809
40. Dandona P., and Aljada A. A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. Am J Cardiol 90 (2002) G27-G33
41. Chao T.H., Li Y.H., Chen J.H., et al. The 161TT genotype in the exon 6 of peroxisome proliferator-activated receptor γ gene is associated with premature acute myocardial infarction and increased lipid peroxidation in habitual heavy smokers. Clin Sci 107 (2004) 461-466
42. Amoruso A., Bardelli C., Gunella G., et al. Quantification of PPAR-gamma protein in monocyte/macrophages from healthy smokers and non-smokers: a possible direct effect of nicotine. Life Sci 81 (2007) 906-915
43. Selvin E., Bolen S., Yeh H.C., et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 168 (2008) 2070-2080
44. Monami M., Marchionni N., and Mannucci E. Winners and losers at the rosiglitazone gamble. A meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone. Diabetes Res Clin Pract 82 (2008) 48-57